The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 302.00
Bid: 301.50
Ask: 305.00
Change: -14.00 (-4.43%)
Spread: 3.50 (1.161%)
Open: 315.50
High: 315.50
Low: 302.00
Prev. Close: 316.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Trading Update

21 Apr 2021 07:00

RNS Number : 0778W
Synthomer PLC
21 April 2021
 

 

21st April 2021

 

Synthomer plc

 

Q1 Trading Update

 

Stronger underlying trading across all divisions and continued exceptional Nitrile Latex performance

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the quarter ended 31st March 2021.

 

Strong trading momentum across all businesses

 

Performance Elastomers

 

Performance Elastomers has continued to perform strongly. The positive trends experienced in our Nitrile Latex business during 2020 have continued through the first quarter of 2021 with overall performance ahead of expectations. Both volumes and unit margins were significantly ahead of prior year driven by exceptional demand as a consequence of the COVID-19 pandemic.

 

Conditions in our SBR latex business also continued to improve, with all segments except paper trading ahead of the comparative period in 2020. Following the strategic review of the European SBR network we completed the consultation in Marl (Germany) and the planned closure of the Oulu (Finland) site at the end of Q1.

 

Functional Solutions

 

Functional Solutions has seen a sustained improvement in the first quarter of 2021. Our consumer facing and industrial end markets have remained robust with our Oil and Gas business improving month on month. Volumes and unit margins were ahead of the comparative period supported by the acquisition of and synergies from OMNOVA and the introduction of low cost capacity in Europe and the US to drive organic growth in differentiated applications.

 

Industrial Specialities and Acrylate Monomers

 

Industrial Specialities also had a good start to the year with activity levels and unit margins significantly ahead of prior year in all major segments including automotive and consumer facing markets. Acrylate Monomers likewise benefitted from improved demand and industry supply issues resulting in a significant uplift in profitability.

 

Reducing Leverage

 

The strong trading performance and cash generation has resulted in a further reduction in proforma net debt:EBITDA to 1.2x at 31st March 2021 with anticipated leverage of less than 1.0x expected by 30th June 2021 (31st December 2020: 1.8x).

 

 

Positive outlook: strong trading increases FY EBITDA expectations

 

Whilst macroeconomic conditions remain uncertain given the ongoing COVID-19 pandemic, we are encouraged by a further strengthening of underlying trading conditions and the strong performances across all our divisions during Q1.

 

Accordingly, the Board now expects 2021 EBITDA to be in excess of £450m reflecting a further rise in the one off profitability of our Nitrile Latex business and the strengthening of the underlying trading conditions. Our expectation that the Nitrile Latex business will return to more normalised levels in 2022 remains unchanged.

 

Conference call

The company will hold a conference call for investors and analysts at 0800 BST today:

 

Dial in number:

UK (Toll free) 0800 640 6441

UK (Local) 020 3936 2999

United States (Local) 1 646 664 1960

All other locations +44 20 3936 2999

 

Access code: 921802

 

 

-ENDS-

 

Further information:

 

Calum MacLean, Chief Executive Officer

Steve Bennett, Chief Financial Officer Tel: +44 1279 436211

Tim Hughes, President, Corporate Development

 

Charles Armitstead/ Matt Denham, Teneo Tel: +44 7703 330 269/ +44 7825 735596

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTIMMATMTTTBAB
Date   Source Headline
5th Aug 20221:20 pmRNSHolding(s) in Company
5th Aug 202211:27 amRNSDirector/PDMR Shareholding
4th Aug 20222:57 pmRNSDirector/PDMR Shareholding
4th Aug 20222:35 pmRNSDirector/PDMR Shareholding
3rd Aug 202212:29 pmRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSResults for the six months ended 30 June 2022
15th Jul 20222:32 pmRNSHolding(s) in Company
8th Jul 202210:23 amRNSHolding(s) in Company
1st Jul 20227:00 amRNSChief Financial Officer
30th Jun 20225:04 pmRNSHolding(s) in Company
21st Jun 20227:00 amRNSAppointment of Non-Executive Director
17th May 202212:55 pmRNSHolding(s) in Company
5th May 202212:39 pmRNSHolding(s) in Company
4th May 20224:46 pmRNSDirector/PDMR Shareholding
4th May 20227:00 amRNSAppointment of Joint Corporate Brokers
28th Apr 202212:24 pmRNSResult of AGM
28th Apr 20227:00 amRNSQ1 2022 trading update
26th Apr 20229:33 amRNSHolding(s) in Company
20th Apr 20224:13 pmRNSHolding(s) in Company
5th Apr 20224:18 pmRNSDirector/PDMR Shareholding
1st Apr 20221:34 pmRNSCompletion of adhesives acquisition
29th Mar 20223:17 pmRNSHolding(s) in Company
29th Mar 20223:14 pmRNSDirector/PDMR Shareholding
25th Mar 20222:03 pmRNSAnnual Financial Report
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:48 pmRNSDirector/PDMR Shareholding
14th Mar 20229:35 amRNSHolding(s) in Company
9th Mar 202212:52 pmRNSDirector/PDMR Shareholding
8th Mar 20223:22 pmRNSDirector/PDMR Shareholding
8th Mar 20223:19 pmRNSDirector/PDMR Shareholding
3rd Mar 20227:00 amRNSPreliminary Results for the year ended 31 Dec 2021
14th Feb 20227:00 amRNSPre-close trading update
10th Feb 20223:10 pmRNSNOTIFICATION OF MAJOR HOLDINGS
22nd Dec 20215:10 pmRNSDirector/PDMR Shareholding
21st Dec 20213:09 pmRNSDirector/PDMR Shareholding
20th Dec 20213:40 pmRNSDirector/PDMR Shareholding
17th Dec 202112:29 pmRNSResults of General Meeting
15th Dec 20212:54 pmRNSDirector/PDMR Shareholding
30th Nov 20214:57 pmRNSPUBLICATION OF CIRCULAR
26th Nov 20217:00 amRNSAppointment of Chief Financial Officer
22nd Nov 202110:36 amRNSDirector Declaration
11th Nov 20212:24 pmRNSDirector/PDMR Shareholding
4th Nov 20212:11 pmRNSDirector/PDMR Shareholding
1st Nov 20217:00 amRNSNew Chief Executive
28th Oct 20213:17 pmRNSResult of Placing
28th Oct 20217:00 amRNSAcquisition
28th Oct 20217:00 amRNSPROPOSED PLACING OF NEW ORDINARY SHARES
30th Sep 20213:08 pmRNSDirectorate Change
10th Sep 20218:23 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.